Codex^® HiCap RNA T7 Polymerase

𝙞𝙣 𝙫𝙞𝙩𝙧𝙤 transcription for advancing RNA medicine

Codex® HiCap RNA Polymerase is a co-transcriptional capping RNA polymerase engineered to produce synthetic RNA to meet increasing demands for safety and cost-effectiveness. The HiCap enzyme generates fewer undesirable double-stranded RNA (dsRNA) byproducts than wild-type T7 (WT T7) RNA polymerase, reducing unwanted immunogenicity, while efficiently incorporating commercially available cap analogs.

dsRNA byproducts

Figure 1. Significantly reduced dsRNA byproducts by Codex HiCap RNA Polymerase. mRNAs were transcribed using either WT T7 or Codex HiCap RNA Polymerase. After IVT was completed, total dsRNA content was quantified via sandwich ELISA using the J2 dsRNA antibody.

Download our brochure for more performance data.

Codex HiCap RNA Polymerase vs. Wild-type T7

Scale to the Clinic with GMP-Grade Codex HiCap

Codex HiCap RNA Polymerase is now offered in GMP-Grade** formats, supporting clinical and commercial RNA production workflows. With reduced double-stranded RNA (dsRNA) byproducts and efficient incorporation of cap analogs, this enzyme helps simplify IVT processes while improving final product quality.

Codex HiCap RNA Polymerase Resources

• Codex HiCap RNA Polymerase Brochure
• Codex HiCap RNA Polymerase in vitro Transcription Procedure
• Codex HiCap RNA Polymerase Guide: Maximizing mRNA Titers
• Poster: HiCap T7 transcribes RNA with higher purity and activity while using less cap analog
• Research Article: An Engineered T7 RNA Polymerase for efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis
• Press Release: Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex HiCap RNA Polymerase

Ordering Information